contact us
Astellas is paying Aquinox Pharmaceuticals $25 million upfront for regional rights to rosiptor. The deal gives Astellas the right to develop the phase 3 SHIP1 activator in Japan and certain other nations in Asia.
Do Not Allow Advertisers to Use My Personal information
